Open AccessSqualene decreased fasting blood glucose level of type ii diabetic rats
Author(s) -
Tri Widyawati,
Siti Syarifah,
Imam Bagus Sumantri
Publication year - 2021
Publication title -
iop conference series. earth and environmental science
Language(s) - English
Resource type - Journals
eISSN - 1755-1307
pISSN - 1755-1315
DOI - 10.1088/1755-1315/912/1/012088
Subject(s) - squalene , metformin , medicine , endocrinology , nicotinamide , type 2 diabetes , streptozotocin , diabetes mellitus , chemistry , biochemistry , enzyme
Squaleneis a chemical compound that has been reported to have antidiabetic activity. The present study aimed to investigate the effect of squalene on fasting blood glucose level (FBGL) in type 2 diabetic rats. Diabetes type II in rats was obtained by giving nicotinamide (120 mg/kg) before high dose streptozotocin (60 mg/kg) intraperitoneally. A total of 18 diabetic rats were divided into 3 groups and served once daily for 12 days as follows; Group I Aquades (Diabetic Control) 10 ml/kg, Group II (Metformin 45 mg/kg) and Group III (Squalene 160 mg/kg). FBGL was measured at day 0, day 6 and day 12. The results showed that FBGL in both Squalene- (194.67 ± 28.32 mg/dL) and Metformin- (178.50 ± 34.27 mg/dL) were significantly decreased after 12 days intervention compared to Diabetic Control-treated groups (438.33 ± 65.79 µmol/L) with p<0.001. This study concluded that squalene was able to decrease FBGL in type II diabetic rats.